Crescent Biopharma, Inc. (CBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Crescent Biopharma, Inc. (CBIO) has a cash flow conversion efficiency ratio of -0.119x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.46 Million) by net assets ($163.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Crescent Biopharma, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Crescent Biopharma, Inc. - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Crescent Biopharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Crescent Biopharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Crescent Biopharma, Inc. ranked by their cash flow conversion efficiency. Explore Crescent Biopharma, Inc. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Forge Global Holdings Inc
NYSE:FRGE
|
-0.055x |
|
Naphtha
TA:NFTA
|
0.097x |
|
Zhejiang Yankon Group Co Ltd
SHG:600261
|
0.022x |
|
Olvi Oyj A
HE:OLVAS
|
0.099x |
|
T'way Air Co Ltd
KO:091810
|
0.196x |
|
Apple Flavor&Fragrance Grp
SHG:603020
|
0.026x |
|
Ridgepost Capital, Inc
NYSE:RPC
|
0.042x |
|
Guizhou Taiyong Changzheng Technology Co Ltd Class A
SHE:002927
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Crescent Biopharma, Inc. (2011–2025)
The table below shows the annual cash flow conversion efficiency of Crescent Biopharma, Inc. from 2011 to 2025. View Crescent Biopharma, Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $203.01 Million | $-71.53 Million | -0.352x | -117.54% |
| 2024-12-31 | $-15.48 Million | $-31.10 Million | 2.009x | +321.26% |
| 2023-12-31 | $38.41 Million | $-34.88 Million | -0.908x | +16.10% |
| 2022-12-31 | $42.93 Million | $-46.46 Million | -1.082x | -53.61% |
| 2021-12-31 | $81.60 Million | $-57.49 Million | -0.704x | -130.19% |
| 2020-12-31 | $128.22 Million | $-39.24 Million | -0.306x | +9.22% |
| 2019-12-31 | $154.20 Million | $-51.98 Million | -0.337x | -59.85% |
| 2018-12-31 | $205.46 Million | $-43.33 Million | -0.211x | +15.20% |
| 2017-12-31 | $119.70 Million | $-29.77 Million | -0.249x | +70.47% |
| 2016-12-31 | $35.30 Million | $-29.73 Million | -0.842x | -313.57% |
| 2015-12-31 | $40.47 Million | $-8.24 Million | -0.204x | -141.64% |
| 2014-12-31 | $50.80 Million | $-4.28 Million | -0.084x | +98.42% |
| 2013-12-31 | $2.91 Million | $-15.54 Million | -5.345x | -539.33% |
| 2012-12-31 | $12.53 Million | $-10.47 Million | -0.836x | -151.03% |
| 2011-12-31 | $8.46 Million | $13.85 Million | 1.638x | -- |
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more